Industry Partner Members

Corcept Therapeutics

We’ve been unlocking the potential of cortisol modulation for more than 25 years.

We’re leading the way in the research and development of cortisol modulators, molecules that regulate cortisol activity at the glucocorticoid receptor (GR). To date, we have discovered more than 1,000 selective proprietary cortisol modulators.

In 2012, we received FDA approval of Korlym^® (mifepristone), the first approved treatment for hypercortisolism (Cushing syndrome).

Today, our team and collaborators continue to unlock the possibilities of cortisol modulation as a way to treat serious diseases. With more than 30 ongoing studies across a wide range of disease areas, including endocrinology, oncology, metabolism, and neurology, we remain dedicated to advance the possibilities of cortisol modulation.

What began as a ripple of scientific truth is now poised to unleash a sea change of discovery representing a fundamental shift in the way we understand and treat disease.

GSK

GSK is focused on maximizing patient survival through transformational medicines. GSK’s oncology pipeline is focused on immuno-oncology, cell therapy, cancer epigenetics and synthetic lethality. Our goal is to achieve a sustainable flow of new treatments based on a diversified portfolio of investigational medicines utilizing modalities such as small molecules, antibodies, antibody drug conjugates and cells, either alone or in combination.

Pfizer Oncology

Our Purpose: We’re in relentless pursuit of breakthroughs that change patients’ lives. We innovate every day to make the world a healthier place. It was Charles Pfizer’s vision at the beginning and it holds true today.

OncoC4

Where science meets the will to fight

Our products come from years of research and development performed by world-renowned immunologists—our founders, Yang Liu, PhD, and Pan Zheng, MD, PhD.

Anchored by a team of business strategists and operations leaders with a proven history of getting products through clinical development, we are poised to offer patients battling evasive cancers a more promising path forward.

Genmab

Genmab is an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.

Merck

Who We Are

We aspire to be the premier research-intensive biopharmaceutical company. We’re at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals.

Lilly

Eli Lilly and Company is a leading innovation-driven corporation and is developing a growing portfolio of best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Indiana, Lilly provides answers – through medicines and information – for some of the world’s most urgent medical needs.

Lilly Oncology is committed to providing comprehensive healthcare solutions – answers that matter – for oncologists and cancer patients around the world through the discovery and development of breakthrough cancer medicines.

Natera

Natera^™ is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives.

Verastem Onocolgoy

Beyond their initial diagnosis, one of the worst things a patient with cancer can hear is that they have run out of options. At Verastem Oncology, we’re on a mission to make sure no patient ever has to hear that news. We embrace the power of partnership and collaboration to develop novel cancer therapies. It’s through these collaborations that we’ll bring hope to patients with RAS pathway-driven cancers. Purposeful. Unwavering. Influential. Insightful. Symbiotic. This is what drives us forward. Together, we look to see where an unexplored pathway will lead us.

BeOne

Our Mission

Build the first next-generation oncology company – one that expands the highest quality therapies to more people around the world – through courage, persistent innovation, and challenging the status quo.

BioNTech

Biopharmaceutical New Technologies (BioNTech) is a global, next generation immunotherapy company pioneering novel, investigative therapies for cancer and other serious diseases. With a steadfast commitment to scientific rigor and operational excellence, BioNTech exploits a wide array of computational discovery and therapeutic modalities with the intent to rapidly develop novel biopharmaceuticals. The company’s diversified portfolio aims to address the full continuum of cancer with oncology product candidates, including mRNA cancer immunotherapies, next-generation immunomodulators and targeted therapies such as antibody-drug conjugates (ADCs) and innovative chimeric antigen receptor (CAR) T cell therapies. Leveraging key capabilities in mRNA research and development, in-house manufacturing, immunology, deep genomics and AI, BioNTech and its collaborators are researching and developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline.

Genentech

Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes biotherapeutics for significant unmet medical needs. Genentech manufactures and commercializes several major oncology drugs include Herceptin, Rituxan, Avastin and Tarceva.

PMVPharma

At PMV, we believe that by specifically targeting each mutant p53 we can fundamentally disrupt the course of cancer. Our research and development efforts are dedicated to selectively targeting mutant p53, providing unique therapies for any patient whose tumor harbors these gene mutations.

REGENERON

Our mission is to use the power of science to bring new medicines to patients … over and over again.

We are a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, almost all of which were homegrown in our laboratories. Regeneron’s medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases and rare diseases.

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite^®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® (RGC) and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

Eisai

Eisai Inc. is a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Our key areas of focus include oncology and neurology (dementia-related diseases and neurodegenerative diseases).

GILEAD

Gilead and Kite Oncology are creating the future of oncology. Making bold strides against cancer requires a strategy built on the power of partnerships, groundbreaking technologies and unexpected clinical combinations. We have purposefully built our pipeline with a focus on depth and breadth to address the greatest unmet needs. From antibody-drug conjugates and small molecules to cell therapy-based approaches, our research and development programs are creating possibilities for people with overlooked, underserved, and difficult-to-treat cancers. We are focused on helping to bring more life to people with cancer and changing the way cancer is treated.